[HTML][HTML] Current trends in the pharmacological management of Chagas disease

V Ribeiro, N Dias, T Paiva, L Hagström-Bex… - International Journal for …, 2020 - Elsevier
Chagas disease (CD) is a tropical neglected illness, affecting mainly populations of low
socioeconomic status in Latin America. An estimated 6 to 8 million people worldwide are …

Myocarditis in humans and in experimental animal models

P Błyszczuk - Frontiers in cardiovascular medicine, 2019 - frontiersin.org
Myocarditis is defined as an inflammation of the cardiac muscle. In humans, various
infectious and non-infectious triggers induce myocarditis with a broad spectrum of …

Resveratrol-like compounds as SIRT1 activators

L Ciccone, E Piragine, S Brogi, C Camodeca… - International Journal of …, 2022 - mdpi.com
The sirtuin 1 (SIRT1) activator resveratrol has emerged as a promising candidate for the
prevention of vascular oxidative stress, which is a trigger for endothelial dysfunction …

ROS and Trypanosoma cruzi: Fuel to infection, poison to the heart

CN Paiva, E Medei, MT Bozza - PLoS Pathogens, 2018 - journals.plos.org
The activation of macrophage respiratory burst in response to infection with Trypanosoma
cruzi inflicts oxidative damage to the host's tissues. For decades, the role of reactive oxygen …

Review of pharmacological options for the treatment of Chagas disease

F Lascano, F García Bournissen… - British journal of clinical …, 2022 - Wiley Online Library
Chagas disease (CD) is a worldwide problem, with over 8 million people infected in both
rural and urban areas. CD was first described over a century ago, but only two drugs are …

Disease Tolerance and Pathogen Resistance Genes May Underlie Trypanosoma cruzi Persistence and Differential Progression to Chagas Disease Cardiomyopathy

C Chevillard, JPS Nunes, AF Frade… - Frontiers in …, 2018 - frontiersin.org
Chagas disease is caused by infection with the protozoan Trypanosoma cruzi and affects
over 8 million people worldwide. In spite of a powerful innate and adaptive immune …

Cardiomyocyte infection by Trypanosoma cruzi promotes innate immune response and glycolysis activation

G Venturini, JM Alvim, K Padilha, CN Toepfer… - Frontiers in cellular …, 2023 - frontiersin.org
Introduction Chagas cardiomyopathy, a disease caused by Trypanosoma cruzi (T. cruzi)
infection, is a major contributor to heart failure in Latin America. There are significant gaps in …

Effects of resveratrol supplementation on cardiac remodeling in hypertensive patients: a randomized controlled clinical trial

X Zheng, J Hai, Y Yang, C Zhang, X Ma, B Kong… - Hypertension …, 2023 - nature.com
Resveratrol (RES) has been demonstrated to be protective in the cardiovascular system in
animal studies, but the evidence is limited in humans. The purpose of the study was to …

Dual and opposite roles of reactive oxygen species (ROS) in Chagas disease: beneficial on the pathogen and harmful on the host

E Maldonado, DA Rojas, S Morales… - Oxidative Medicine …, 2020 - Wiley Online Library
Chagas disease is a neglected tropical disease, which affects an estimate of 6‐7 million
people worldwide. Chagas disease is caused by Trypanosoma cruzi, which is a eukaryotic …

AMP-activated protein kinase and host defense against infection

P Silwal, JK Kim, JM Yuk, EK Jo - International journal of molecular …, 2018 - mdpi.com
5′-AMP-activated protein kinase (AMPK) plays diverse roles in various physiological and
pathological conditions. AMPK is involved in energy metabolism, which is perturbed by …